Valuation: Unicycive Therapeutics, Inc.

Market Cap 103M 91.92M 85.28M 77.66M 146M 9.8B 149M 1.03B 401M 5.1B 387M 379M 16.29B P/E 2026 *
-2.84x
P/E 2027 * 1.96x
Enterprise Value 103M 91.92M 85.28M 77.66M 146M 9.8B 149M 1.03B 401M 5.1B 387M 379M 16.29B EV / Sales 2026 *
75.2x
EV / Sales 2027 * 0.69x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * 57.9%
1 day-2.97%
1 week-14.11%
Current month-23.54%
1 month-30.29%
3 months-31.23%
6 months-48.27%
Current year-37.78%
1 week 3.56
Extreme 3.56
4.2
1 month 3.56
Extreme 3.56
4.97
Current year 3.56
Extreme 3.56
8.74
1 year 3.56
Extreme 3.56
8.74
3 years 2.02
Extreme 2.02
18.18
5 years 2.02
Extreme 2.02
31.3
10 years 2.02
Extreme 2.02
87.3
Manager TitleAgeSince
Chief Executive Officer 53 2016-08-17
Director of Finance/CFO 64 2021-02-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Chairman 53 2016-08-17
Director/Board Member 58 2017-12-31
Director/Board Member 58 2023-09-05
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Free

Chief Operating Officer

169,500 0.6716%
5/14/26 Free

Executive/Senior Manager

169,500 0.6716%
5/14/26 Free

Chief Financial Officer

169,500 0.6716%
Change 5-day change 1-year change 3-year change Capi.($)
-2.97%-14.11%-21.27%-58.16% 103M
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+5.01%+32.37%+35.96% 43.13B
-2.20%-5.78%+298.44%+532.76% 41.48B
+6.43%+2.76%+16.56%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-5.30%-12.09%-12.92% 22.27B
Average +1.05%-4.66%+45.38%+82.68% 37.31B
Weighted average by Cap. +1.58%-3.49%+56.55%+105.26%

Financials

2026 *2027 *
Net sales 1.37M 1.22M 1.13M 1.03M 1.94M 130M 1.98M 13.63M 5.33M 67.84M 5.14M 5.03M 217M 150M 133M 124M 113M 212M 14.21B 216M 1.49B 582M 7.4B 561M 549M 23.64B
Net income -35.38M -31.56M -29.28M -26.66M -50.22M -3.36B -51.15M -352M -138M -1.75B -133M -130M -5.59B 57.12M 50.94M 47.27M 43.04M 81.07M 5.43B 82.58M 568M 222M 2.83B 214M 210M 9.03B
Net Debt - -
Projected Income Statement - Annual - Unicycive Therapeutics, Inc.
Logo Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Employees
22
Date Price Change Volume
26-10-15 US$3.590 -2.97% 892,200
26-10-14 US$3.700 -0.80% 1,208,828
26-10-13 US$3.730 -7.90% 1,840,063
26-10-12 US$4.050 -1.46% 912,907
26-10-09 US$4.110 +0.98% 551,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Unicycive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.700USD
Average target price
28.40USD
Spread / Average Target
+667.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Unicycive Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. UNCY Stock